GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Float Percentage Of Total Shares Outstanding

Hansa Biopharma AB (OSTO:HNSA) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hansa Biopharma AB's float shares is 0.00 Mil. Hansa Biopharma AB's total shares outstanding is 63.09 Mil. Hansa Biopharma AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hansa Biopharma AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hansa Biopharma AB's Institutional Ownership is 4.15%.

Hansa Biopharma AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Hansa Biopharma AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/63.09
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
OSTO:IBT B OSTO:FLUO OSTO:XSPRAY OSTO:EGTX OSTO:BINV OSTO:VICO OSTO:ONCO OSTO:CANTA OSTO:XBRANE XSAT:CURAS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HNSBF:USA 0RC7:UK 24H:Germany
Address
Scheelevagen 22, Lund, SWE, 223 63
Website
https://www.hansabiopharma.com
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines